Form 4: TuHURA CEO Bianco Granted 610,332 Stock Options

TuHURA Biosciences, Inc. CEO James A. Bianco received a supplemental grant of 610,332 stock options with an exercise price of $0.73.

Summary

• James A. Bianco, Chief Executive Officer and Director of TuHURA Biosciences, Inc. (HURA), was granted 610,332 stock options.
• The options have an exercise price of $0.73 per share.
• The transaction date for this grant was January 6, 2026.
• The options are exercisable in three equal annual installments, with one-third vesting on January 6, 2026, January 6, 2027, and January 6, 2028.
• The expiration date for these options is January 6, 2036.
• The grant is a supplemental option grant to one previously made in December 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally a positive signal as it aligns management's interests with shareholders. It's a standard compensation event, not directly indicative of operational performance, but reflects ongoing executive incentive structures.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The establishment of a Rule 10b5-1(c) plan demonstrates a structured approach to executive compensation and potential future stock transactions.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Executive compensation, particularly through stock options, is a common practice in the biotechnology and pharmaceutical industries to attract and retain top talent, and to align leadership incentives with long-term shareholder value creation. The exercise price of $0.73 suggests a valuation context for the company's equity at the time of the grant.

Comparison to Industry Standards

• The grant of stock options to a CEO is a standard component of executive compensation packages across the biotech industry, comparable to practices at companies like Moderna or BioNTech, which heavily utilize equity-based incentives.
• The vesting schedule, typically over three to four years, is also common, designed to encourage long-term commitment and performance, similar to grants observed at emerging biotech firms such as Recursion Pharmaceuticals or Ginkgo Bioworks.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the CEO's financial incentives with the long-term performance of the company, potentially benefiting shareholders if the stock price increases.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, which can positively influence employee morale.

Next Steps

• The stock options will vest in three annual installments on January 6, 2026, January 6, 2027, and January 6, 2028.

Key Dates

Keywords

TuHURA Biosciences, HURA, stock options, executive compensation, insider transaction, Form 4, James A. Bianco, CEO, Rule 10b5-1